Speak with me

Recent changes.

Catalyst dates move. This page lists every date on the biotech catalyst calendar that has changed in the last 30 days, and every row withdrawn in that period, with the date it moved from. A row that moves keeps its identity, so a calendar subscription updates the event in place rather than adding a second one. Nothing is ever deleted quietly.

Last compiled .

WasNowLaneCompanyEventSource
15 Jan 2027ClinicalMoonLake Immunotherapeutics AGAs of 9 October 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Arthritis, Psoriatic, on 4 January 2027.NCT06641089
18 Nov 2026ClinicalCSL BehringAs of 18 August 2026, CSL Behring estimated primary completion of a Phase 3 trial in Complex Cardiovascular Surgery With Cardiopulmonary Bypass, on 6 April 2027.NCT07094087
18 Sept 2026ClinicalHan Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairAs of 8 October 2026, Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair estimated primary completion of a Phase 3 trial in sCLC, on 18 December 2026.NCT07145333
31 Dec 2026ClinicalHoffmann-La RocheAs of 8 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in cancer, on 30 November 2026.NCT03148418
1 Oct 2026ClinicalIngenia Therapeutics INCAs of 7 October 2026, Ingenia Therapeutics estimated primary completion of a Phase 2 trial in Healthy Volunteers, in December 2026.NCT07231679
19 Sept 2026ClinicalTeva Branded Pharmaceutical Products R&D LLCAs of 6 October 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 2 November 2026.NCT06664619
1 Dec 2026ClinicalTBF Genie TissulaireAs of 6 October 2026, TBF Genie Tissulaire estimated primary completion of a Phase 2 trial in Osteoarthritis Hand, in November 2026.NCT06038331
2 Apr 2027ClinicalAstraZenecaAs of 6 October 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Staphylococcus Aureus, on 8 March 2027.NCT06749457
1 Dec 2026ClinicalVantive Health LLCAs of 5 October 2026, Vantive Health estimated primary completion of a Phase 3 trial in Regional Citrate Anticoagulation (RCA), in January 2027.NCT05399537
1 Nov 2026ClinicalBeOne MedicinesAs of 5 October 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in B-cell Malignancy, in March 2027.NCT05006716
30 Jan 2027ClinicalHoffmann-La RocheAs of 2 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Moderately to Severely Active Ulcerative Colitis, on 29 October 2026.NCT06588855
1 Feb 2027ClinicalIonis Pharmaceuticals, Inc.As of 18 September 2026, Ionis Pharmaceuticals estimated primary completion of a Phase 2 trial in Prion Disease, in April 2027.NCT06153966
6 Nov 2026ClinicalMerck Sharp & Dohme LLCAs of 2 October 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hodgkin Lymphoma, on 12 February 2027.NCT03407144
16 Dec 2026ClinicalMerck Sharp & Dohme LLCAs of 12 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Invasive Fungal Infection, on 31 March 2027.NCT04665037
31 Dec 2026ClinicalNewron Pharmaceuticals SPAAs of 10 September 2026, Newron Pharmaceuticals SPA estimated primary completion of a Phase 3 trial in Treatment-resistant Schizophrenia, on 31 March 2027.NCT07184619
31 Dec 2026ClinicalRemedyAs of 19 August 2026, Remedy estimated primary completion of a Phase 2 trial in Post Traumatic Stress Disorder, on 31 March 2027.NCT06044675
31 Oct 2026ClinicalViatris Innovation GmbHAs of 15 September 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 March 2027.NCT05648500
1 Dec 2026ClinicalVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAAs of 30 September 2026, Verona Pharma estimated primary completion of a Phase 2 trial in cOPD, on 1 March 2027.NCT05270525
25 Aug 2026ClinicalSanofiAs of 1 October 2026, Sanofi estimated primary completion of a Phase 2 trial in Graves' Disease, on 11 February 2027.NCT06984627
25 Dec 2026ClinicalBoehringer IngelheimAs of 30 September 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Geographic Atrophy, on 22 December 2026.NCT06769048
30 Sept 2026ClinicalUCB Biopharma SRLAs of 29 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 31 October 2026.NCT05077904
1 Sept 2026ClinicalSuzhou Suncadia Biopharmaceuticals Co., Ltd.As of 25 September 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocellular Carcinoma, in October 2026.NCT06618664
1 Sept 2026ClinicalPfizerAs of 2 September 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 24 March 2027.NCT05548127
2 Sept 2026ClinicalBoehringer IngelheimAs of 1 October 2026, Boehringer Ingelheim estimated primary completion of a Phase 3 trial in Lung Cancer, Non-squamous, Non-small Cell, on 10 December 2026.NCT06151574
21 Aug 2026ClinicalEMD Serono Research & Development Institute, Inc.As of 22 September 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 3 trial in Solid Tumors, on 24 November 2026.NCT03815643
1 Oct 2026ClinicalNovartis PharmaceuticalsAs of 22 September 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration, on 30 September 2026.NCT05230537
15 Sept 2026ClinicalMerck Sharp & Dohme LLCAs of 18 September 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Endometrial Neoplasms, on 20 November 2026.NCT04634877
21 Aug 2026ClinicalLongboard PharmaceuticalsAs of 17 September 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Dravet Syndrome, on 31 December 2026.NCT06660394
15 Aug 2026ClinicalPMV Pharmaceuticals, IncAs of 2 October 2026, PMV Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 15 December 2026.NCT04585750
11 Sept 2026ClinicalNS Pharma, Inc.As of 15 September 2026, NS Pharma estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 26 February 2027.NCT05996003
31 Oct 2026ClinicalViatris Innovation GmbHAs of 15 September 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 December 2026.NCT05672576
1 Sept 2026ClinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd.As of 15 September 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer, in February 2027.NCT07367516
1 Sept 2026ClinicalQlaris Bio, Inc.As of 14 September 2026, Qlaris Bio estimated primary completion of a Phase 2 trial in Non-proliferative Diabetic Retinopathy (NPDR), in October 2026.NCT07354477
23 Aug 2026ClinicalPfizerAs of 14 September 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 26 February 2027.NCT05262400
9 Feb 2027ClinicalENA Respiratory Pty LtdAs of 11 September 2026, ENA Respiratory Pty estimated primary completion of a Phase 2 trial in Viral Respiratory Infection, on 12 March 2027.NCT07222670
1 Sept 2026ClinicalGilead SciencesAs of 11 September 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in March 2027.NCT05186974